Cargando…

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)

BACKGROUND: We aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease (IBD) centre. METHODS: All adult patients with IBD on standard dosing CT-P13 (5 mg/kg 8 week...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carbery, Isabel, Burdge, Gemma, Clark, Tanya, Broglio, Giacomo, Greer, Dan, Alakkari, Alaa, Selinger, Christian Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950917/ https://www.ncbi.nlm.nih.gov/pubmed/36813298 http://dx.doi.org/10.1136/bmjgast-2023-001105

Ejemplares similares

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
por: Burdge, Gemma, et al.
Publicado: (2022)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
por: Sekhri, Shaina, et al.
Publicado: (2021)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease
por: Phillips, Jennifer, et al.
Publicado: (2023)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse
por: Robinson, A, et al.
Publicado: (2013)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study
por: Minami, Naoki, et al.
Publicado: (2015)

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD
por: Selinger, Christian Philipp, et al.
Publicado: (2021)

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
por: Argüelles-Arias, Federico, et al.
Publicado: (2017)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
por: Goessens, Laurent, et al.
Publicado: (2021)

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
por: Jongsma, Maria M E, et al.
Publicado: (2022)

Current smoking habits in British IBD patients in the age of e-cigarettes
por: Chong, Chui, et al.
Publicado: (2019)

Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Changing paradigms in management of inflammatory bowel disease
por: Mao, Ren, et al.
Publicado: (2022)

Environmental risk factors for inflammatory bowel disease
por: Singh, Noreen, et al.
Publicado: (2022)

New endoscopic tools in inflammatory bowel disease
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Can adjuncts to bowel preparation for colonoscopy improve patient experience and result in superior bowel cleanliness? A systematic review and meta-analysis
por: Kamran, Umair, et al.
Publicado: (2020)

Ultrasonography in inflammatory bowel disease – So far we are?
por: Christian, Maaser, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Is hypertension an extra‐intestinal manifestation of inflammatory bowel disease?
por: Burisch, Johan
Publicado: (2023)

Avoiding food avoidance in patients with inflammatory bowel disease
por: Godny, Lihi, et al.
Publicado: (2023)

Faecal metabolome and its determinants in inflammatory bowel disease
por: Vich Vila, Arnau, et al.
Publicado: (2023)

Physical Fitness in Adolescence and Subsequent Inflammatory Bowel Disease Risk
por: Melinder, Carren, et al.
Publicado: (2015)

Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?
por: D'Amico, Ferdinando, et al.
Publicado: (2022)

Identifying and understanding disease burden in patients with inflammatory bowel disease
por: Christensen, Katrine Risager, et al.
Publicado: (2022)

Inflammatory bowel disease cross‐sectional imaging: What's new?
por: Wang, Yang‐di, et al.
Publicado: (2022)

The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis
por: Zheng, Jiaying, et al.
Publicado: (2022)

Smoking and colorectal cancer in inflammatory bowel disease: Quantity matters?
por: Marafini, Irene, et al.
Publicado: (2023)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation
por: Alhmoud, Tarik, et al.
Publicado: (2020)

Implications of the changing epidemiology of inflammatory bowel disease in a changing world
por: Agrawal, Manasi, et al.
Publicado: (2022)

The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
por: Aniwan, Satimai, et al.
Publicado: (2022)

Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD
por: Lee, Thomas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8h1534no0rc6dsuntk27dqt62u